Paris, 15 March 2022
Summary
Prescrire welcomes the stronger focus on the prevention of medication errors, the introduction of a preliminary assessment by marketing authorisation holders (MAH) and the opposition to "umbrella brands".
But Prescrire also expressed concerns, especially as regards:
- The correct use of International Non-proprietary Names (INN) by the European Medicines Agency (EMA) and MAH;
- Threats to EMA's independence, if the agency becomes involved in negotiations with companies for possible re-use or "conditional acceptability" of names, in which the Agency seems to be taking on the role of a "broker" in an unnecessary trade-name recycling market.
> Click here to download Prescrire's response (pdf, 503 Ko)
©Prescrire March 2022
Share |
 |
 |